Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MIV-410
- Development stage
- Discontinued
- Lead developer
- Medivir
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MIV-410 is a small molecule nucleoside analog prodrug developed by Medivir for the treatment of shingles (Herpes Zoster). It is designed to be converted in vivo into its active metabolite, 2',3'-dideoxy-3'-fluoroguanosine (FLG). The active triphosphate form of FLG acts as a potent and selective inhibitor of viral DNA polymerase, specifically targeting the Varicella-zoster virus (VZV). By competing with natural deoxyguanosine triphosphate (dGTP), it incorporates into the nascent viral DNA strand and causes premature chain termination, thereby halting viral replication. Although MIV-410 demonstrated efficacy in Phase 2 clinical trials, its development was terminated by Medivir in the early 2000s.
- Other names
- FLG prodrug
Beyond the preview
Go deeper on MIV-410.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MIV-410.